HCRT and Alzheimer disease: Furthermore, the administration of orexin significantly increased the Aβ levels in ISF during the light phase and orexin receptors antagonist led to the inhibition of the diurnal fluctuation of Aβ in ISF of AD model mice (Kang et al., 2009).